The “RHINIL-2” clinical study was carried out in 2022 by ALYATEC in Strasbourg in collaboration with research teams from AP-HP (Assistance Publique – Hôpitaux de Paris). The allergen exposure chamber was used to evaluate the efficacy and tolerance of ILT-101 treatment, based on low dose IL-2 (Interleukin-2), on patients allergic to birch pollen.
This is a phase 2a study which indicates the treatment was well-tolerated by the participants and highlights its action to reduce allergic rhinitis and asthma symptoms. The results were published in the Journal of Allergy and Clinical Immunology on November 10, 2024.
This study included 24 participants and opens the way to a larger trial to validate the therapeutic potential of IL-2 for allergic diseases.
Rosenzwajg, Michelle et al. Low-dose interleukin-2 in birch pollen allergy: a phase-2 randomized double-blind placebo-controlled trial; Journal of Allergy and Clinical Immunology, 2024 https://doi.org/10.1016/j.jaci.2024.10.033
